CU20230011A7 - Composiciones y métodos de fabricación de células t - Google Patents

Composiciones y métodos de fabricación de células t

Info

Publication number
CU20230011A7
CU20230011A7 CU2023000011A CU20230011A CU20230011A7 CU 20230011 A7 CU20230011 A7 CU 20230011A7 CU 2023000011 A CU2023000011 A CU 2023000011A CU 20230011 A CU20230011 A CU 20230011A CU 20230011 A7 CU20230011 A7 CU 20230011A7
Authority
CU
Cuba
Prior art keywords
cells
compositions
specific
manufacturing methods
antigen
Prior art date
Application number
CU2023000011A
Other languages
English (en)
Spanish (es)
Inventor
Jaewon Choi
Brandon Conn
Jared Dietze
Vikram Juneja
Original Assignee
Biontech Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc filed Critical Biontech Us Inc
Publication of CU20230011A7 publication Critical patent/CU20230011A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Moulding By Coating Moulds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CU2023000011A 2020-08-13 2021-08-12 Composiciones y métodos de fabricación de células t CU20230011A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063065327P 2020-08-13 2020-08-13
PCT/US2021/045800 WO2022036137A1 (en) 2020-08-13 2021-08-12 T cell manufacturing compositions and methods

Publications (1)

Publication Number Publication Date
CU20230011A7 true CU20230011A7 (es) 2023-12-07

Family

ID=80248187

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2023000011A CU20230011A7 (es) 2020-08-13 2021-08-12 Composiciones y métodos de fabricación de células t

Country Status (14)

Country Link
US (1) US20230374455A1 (https=)
EP (1) EP4196135A4 (https=)
JP (1) JP2023539056A (https=)
KR (1) KR20230074719A (https=)
CN (1) CN116710551A (https=)
AU (1) AU2021325081A1 (https=)
BR (1) BR112023002733A2 (https=)
CA (1) CA3189285A1 (https=)
CL (1) CL2023000437A1 (https=)
CO (1) CO2023002953A2 (https=)
CU (1) CU20230011A7 (https=)
IL (1) IL300564A (https=)
MX (1) MX2023001815A (https=)
WO (1) WO2022036137A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
CN119317705A (zh) * 2022-02-15 2025-01-14 马克治疗公司 用于抗原特异性t细胞扩增的组合物和方法
CA3254900A1 (en) * 2022-03-30 2023-10-05 Mdx Management Llc COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS
WO2024260318A1 (zh) * 2023-06-19 2024-12-26 苏州沙砾生物科技有限公司 一种肿瘤特异性细胞的富集方法和应用
WO2025245488A2 (en) * 2024-05-24 2025-11-27 Biontech Us Inc. Compositions and methods for t cell manufacturing and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
SG11202004116QA (en) * 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
EP3844265A2 (en) * 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
AR118859A1 (es) * 2019-05-08 2021-11-03 Neon Therapeutics Inc Composiciones y métodos de fabricación de células t

Also Published As

Publication number Publication date
MX2023001815A (es) 2023-04-11
JP2023539056A (ja) 2023-09-13
IL300564A (en) 2023-04-01
AU2021325081A1 (en) 2023-04-13
EP4196135A4 (en) 2024-08-21
US20230374455A1 (en) 2023-11-23
EP4196135A1 (en) 2023-06-21
BR112023002733A2 (pt) 2023-05-02
CO2023002953A2 (es) 2023-05-19
CN116710551A (zh) 2023-09-05
CL2023000437A1 (es) 2023-07-28
KR20230074719A (ko) 2023-05-31
WO2022036137A1 (en) 2022-02-17
CA3189285A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
MX2021013608A (es) Composiciones y métodos de fabricacion de celulas t.
CU20230011A7 (es) Composiciones y métodos de fabricación de células t
BR112014006176A2 (pt) rna transcrito in vitro ou rna sintético, célula t, e, métodos para gerar uma população de células t geneticamente modificadas por rna, e para tratar um paciente com cancer
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
MX2020009773A (es) Terapia de combinacion.
CO6362050A2 (es) Vectores de terapia de gen y desaminasas citosina
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
AR109707A1 (es) Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre
MX362653B (es) Composiciones de alta densidad de partícula que comprenden complejos de nanoesferas bioabsorbibles biocompatibles y sus usos.
MX2021011608A (es) Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
BR112021024946A2 (pt) Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero
BR112023013052A2 (pt) Anticorpo monoclonal contra mac-1 humano e seus usos
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
MX2022008648A (es) Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
BR112021021787A2 (pt) Terapias de combinação
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
MX2025013867A (es) Metodos para tratar el cancer en sujetos con exposicion previa a inhibidores de punto de control inmunitario
MX2021001764A (es) Terapia de combinacion.
MX2025006565A (es) Terapia contra el cancer con capivasertib y fulvestrant